Abstract
BACKGROUND: Dendritic cells (DCs) are professional antigen-presenting cells that mediate the response to inhaled allergen. A major division in DC ontogeny exists between myeloid DCs (mDCs) and plasmacytoid DCs (pDCs). A subtype of mDC expressing thrombomodulin, termed myeloid DCs type 2 (mDC2s), has been identified in both the circulation and lung and has recently been suggested to have a role in allergic asthma. OBJECTIVE: To investigate changes in circulating and sputum mDC2s after allergen inhalation in subjects with asthma. METHODS: Peripheral blood and induced sputum were obtained before and 3, 7, and 24 h after inhalation of diluent and allergen from allergic asthmatic subjects who develop both allergen-induced early- and late-phase responses. mDC2s were measured by flow cytometry. Soluble BDCA-3 (thrombomodulin) was measured in sputum by ELISA. RESULTS: The number of sputum mDC2s significantly increased 24 h after allergen challenge compared with diluent. The expression of BDCA-3 on sputum mDCs also increased, albeit non-significantly, at 7 and 24 h after allergen. Soluble BDCA-3 in sputum and the number of circulating mDC2s were not different between allergen and diluent. CONCLUSIONS AND CLINICAL RELEVANCE: Myeloid DCs type 2 (mDC2s) increase in the sputum of subjects with asthma after allergen challenge, suggesting this subtype of mDC is involved in the regulation of allergen responses in the lung.
Original language | English |
---|---|
Journal | Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology |
Volume | 44 |
Issue number | 7 |
DOIs | |
Publication status | Published - Jul 2014 |
Keywords
- allergen challenge
- allergic asthma
- induced sputum
- inflammatory cells
- thrombomodulin